Ear Nose Throat Disorders
Altamira’s Bentrio nasal spray trial meets primary efficacy endpoint
Altamira Therapeutics has reported that the NASAR clinical trial of Bentrio nasal spray for seasonal allergic rhinitis (SAR) has met…
Lyra restarts second pivotal Phase III trial of LYR-210 nasal implant
Lyra Therapeutics has restarted screening and enrolment of patients in its second pivotal Phase III clinical trial, ENLIGHTEN II, of…
MHRA authorises Decibel’s CTA for trial of DB-OTO in paediatric patients
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised Decibel Therapeutics’ clinical trial application (CTA) for initiating a…
Sensorion reports first patient enrolment in Phase IIa ototoxicity trial
Sensorion has reported the enrolment of the first patient in its Phase IIa proof of concept clinical trial of SENS-401…
Lyra Therapeutics enrols first subject in Phase III CRS therapy trial
Lyra Therapeutics has enrolled the first subject in the Phase III ENLIGHTEN II clinical trial to evaluate its investigational product…
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
DCT Adoption Tracker reveals top therapy areas using a decentralisation approach
Telemedicine remains the leading decentralisation approach in clinical trials in Q2 of this year. The continued rise of telemedicine as…
Sensorion’s sudden sensorineural hearing loss asset fails Phase II test
Sensorion announced that the Phase II AUDIBLE-S clinical trial of its drug candidate SENS-401 (Arazasetron) to treat sudden sensorineural hearing…
Frequency’s Phase IIa hearing loss trial shows no benefit versus placebo
Day-90 data from a Phase IIa study of four dosing regimens of Frequency Therapeutics’ hearing loss treatment FX-322 in subjects…
Sensorion gets approval to add new sites to Phase II trial of SENS-401
Biotech firm Sensorion has received approval from the Independent Ethics Committee of Strasbourg in France to add new military sites…
Bellus Health starts recruitment in Phase II chronic cough trial
Canadian biopharmaceutical firm Bellus Health has commenced patient enrolment in the Phase II RELIEF clinical trial of BLU-5937 to treat…